Literature DB >> 32158927

CD36: a key mediator of resistance to HER2 inhibitors in breast cancer.

William W Feng1,2, Scott Bang1, Manabu Kurokawa1,2.   

Abstract

Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  FASN; FATP; lapatinib; lipid metabolism; trastuzumab

Year:  2020        PMID： 32158927      PMCID： PMC7051136          DOI： 10.1080/23723556.2020.1715766

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.

Authors:  Manabu Kurokawa; Jiyeon Kim; Joseph Geradts; Kenkyo Matsuura; Liu Liu; Xu Ran; Wenle Xia; Thomas J Ribar; Ricardo Henao; Mark W Dewhirst; Wun-Jae Kim; Joseph E Lucas; Shaomeng Wang; Neil L Spector; Sally Kornbluth
Journal:  Sci Signal       Date:  2013-05-07       Impact factor: 8.192

Review 2.  Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Authors:  Rita Nahta; Dihua Yu; Mien-Chie Hung; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Nat Clin Pract Oncol       Date:  2006-05

Review 3.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.

Authors:  Javier A Menendez; Ruth Lupu
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

Review 4.  Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Authors:  Brent N Rexer; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Cell Cycle       Date:  2009-01-30       Impact factor: 4.534

5.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

6.  Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.

Authors:  Chandan Kumar-Sinha; Kathleen Woods Ignatoski; Marc E Lippman; Stephen P Ethier; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

Review 7.  CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior.

Authors:  Roy L Silverstein; Maria Febbraio
Journal:  Sci Signal       Date:  2009-05-26       Impact factor: 8.192

Review 8.  Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS).

Authors:  Yan Du; Jon Fryzek; Mikkael A Sekeres; Emanuela Taioli
Journal:  Leuk Res       Date:  2009-09-10       Impact factor: 3.156

9.  Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

Authors:  Quanri Jin; Linda X Yuan; Delphine Boulbes; Jong Min Baek; Ying Nai Wang; Daniel Gomez-Cabello; David H Hawke; Sai Ching Yeung; Mong Hong Lee; Gabriel N Hortobagyi; Mien Chie Hung; Francisco J Esteva
Journal:  Breast Cancer Res       Date:  2010-11-16       Impact factor: 6.466

10.  CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.

Authors:  William W Feng; Owen Wilkins; Scott Bang; Matthew Ung; Jiaqi Li; Jennifer An; Carmen Del Genio; Kaleigh Canfield; James DiRenzo; Wendy Wells; Arti Gaur; R Brooks Robey; Jessie Yanxiang Guo; Ryan L Powles; Christos Sotiriou; Lajos Pusztai; Maria Febbraio; Chao Cheng; William B Kinlaw; Manabu Kurokawa
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423
  10 in total
  3 in total

Review 1.  An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.

Authors:  Ahmed M Elshazly; David A Gewirtz
Journal:  Cancer Drug Resist       Date:  2022-06-01

Review 2.  Targeting lipid metabolism in the treatment of ovarian cancer.

Authors:  Saliha Chaudhry; Stefani N Thomas; Glenn E Simmons
Journal:  Oncotarget       Date:  2022-05-25

3.  In Vivo Optical Metabolic Imaging of Long-Chain Fatty Acid Uptake in Orthotopic Models of Triple-Negative Breast Cancer.

Authors:  Megan C Madonna; Joy E Duer; Joyce V Lee; Jeremy Williams; Baris Avsaroglu; Caigang Zhu; Riley Deutsch; Roujia Wang; Brian T Crouch; Matthew D Hirschey; Andrei Goga; Nirmala Ramanujam
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.